Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | FPR2 | P25090 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10952765 | 0.84 | NPSR1 (0.53) | HPGDSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2403850 | 0.82 | MEN1 (0.62) | MEN1KMT2AHPGDALDH1A1LMNA | |
| SCHEMBL13966687 | 0.82 | NPC1 (0.53) | MEN1KMT2AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL12319372 | 0.82 | POLB (0.42) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL3447255 | 0.82 | LMNA (0.50) | MEN1KMT2ASMN1; SMN2POLBLMNA | |
| SCHEMBL10951354 | 0.81 | TSHR (0.63) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL9502356 | 0.76 | MAPT (0.55) | MEN1KMT2AFPR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL969565 | 0.75 | KMT2A (0.73) | MEN1KMT2AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL2105705 | 0.73 | TSHR (0.69) | MEN1KMT2AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL31345023 | 0.73 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-7119120-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1465638-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019113-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003057225-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019113-A1 | Phosphate transport inhibitors | SLC34A1, SLC34A2, SLC20A1 | MEN1 2905/4885KMT2A 4536/4885HPGD 854/4885 |
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | MEN1 2248/4885KMT2A 4634/4885HPGD 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.